A study to investigate safety, tolerability, pharmacokinetics, and pharmacodynamics of AZD1705 in participants with dyslipidemia

Study identifier:D7650C00001

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Recruiting

Official Title

A Phase I Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD1705 Following Single and Multiple Ascending Doses in Participants with Dyslipidemia

Medical condition

Cardiovascular

Phase

Phase 1

Healthy volunteers

Yes

Study drug

AZD1705

Sex

All

Estimated Enrollment

112

Study type

Interventional

Age

18 Years - 65 Years

Date

Study Start Date: 16 Jan 2024
Estimated Primary Completion Date: 10 Nov 2025
Estimated Study Completion Date: 10 Nov 2025

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Sequential Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Jan 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

PAREXEL

Inclusion and exclusion criteria